Compare WEX & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEX | GKOS |
|---|---|---|
| Founded | 1983 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.3B |
| IPO Year | 2005 | 2015 |
| Metric | WEX | GKOS |
|---|---|---|
| Price | $157.53 | $120.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | ★ $171.36 | $127.71 |
| AVG Volume (30 Days) | 332.1K | ★ 677.3K |
| Earning Date | 02-04-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.64 | N/A |
| Revenue | ★ $2,624,500,000.00 | $469,820,000.00 |
| Revenue This Year | $1.74 | $31.33 |
| Revenue Next Year | $4.11 | $24.01 |
| P/E Ratio | $20.65 | ★ N/A |
| Revenue Growth | N/A | ★ 30.38 |
| 52 Week Low | $110.45 | $73.16 |
| 52 Week High | $188.70 | $163.71 |
| Indicator | WEX | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 64.15 |
| Support Level | $157.47 | $93.96 |
| Resistance Level | $164.01 | $115.00 |
| Average True Range (ATR) | 4.07 | 4.48 |
| MACD | 0.54 | -0.42 |
| Stochastic Oscillator | 62.87 | 94.40 |
WEX Inc is a provider of corporate payment solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. The company's prime end market is the United States of America.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.